

Fill in this information to identify the case:

United States Bankruptcy Court for the:

District of Delaware

(State)

Case number (if known): Chapter 11

☐ Check if this is an amended filing**Official Form 201****Voluntary Petition for Non-Individuals Filing for Bankruptcy**

06/22

If more space is needed, attach a separate sheet to this form. On the top of any additional pages, write the debtor's name and the case number (if known). For more information, a separate document, *Instructions for Bankruptcy Forms for Non-Individuals*, is available.

1. **Debtor's name** SevenScore Pharmaceuticals, LLC

2. **All other names debtor used in the last 8 years** Orphan Star Therapeutics, LLC

Include any assumed names, trade names, and *doing business* as names

3. **Debtor's federal Employer Identification Number (EIN)** 8 2 - 5 0 9 2 5 9 8

4. Debtor's address**Principal place of business**

600 3rd Avenue

Number Street

19th Floor

New York

City

NY

State

10016

ZIP Code

New York

County

Mailing address, if different from principal place of business

Number Street

P.O. Box

City

State

ZIP Code

Location of principal assets, if different from principal place of business

Number Street

City

State

ZIP Code

5. **Debtor's website (URL)** <https://www.sevenscorepharma.com>

Debtor SevenScore Pharmaceuticals, LLC
Name

Case number (if known) _____

6. Type of debtor

- ☒ Corporation (including Limited Liability Company (LLC) and Limited Liability Partnership (LLP))
☐ Partnership (excluding LLP)
☐ Other. Specify: _____

7. Describe debtor's business*A. Check one:*

- ☐ Health Care Business (as defined in 11 U.S.C. § 101(27A))
☐ Single Asset Real Estate (as defined in 11 U.S.C. § 101(51B))
☐ Railroad (as defined in 11 U.S.C. § 101(44))
☐ Stockbroker (as defined in 11 U.S.C. § 101(53A))
☐ Commodity Broker (as defined in 11 U.S.C. § 101(6))
☐ Clearing Bank (as defined in 11 U.S.C. § 781(3))
☒ None of the above

B. Check all that apply:

- ☐ Tax-exempt entity (as described in 26 U.S.C. § 501)
☐ Investment company, including hedge fund or pooled investment vehicle (as defined in 15 U.S.C. § 80a-3)
☐ Investment advisor (as defined in 15 U.S.C. § 80b-2(a)(11))

*C. NAICS (North American Industry Classification System) 4-digit code that best describes debtor. See <http://www.uscourts.gov/four-digit-national-association-naics-codes>.*3 2 5 4**8. Under which chapter of the Bankruptcy Code is the debtor filing?**

A debtor who is a "small business debtor" must check the first sub-box. A debtor as defined in § 1182(1) who elects to proceed under subchapter V of chapter 11 (whether or not the debtor is a "small business debtor") must check the second sub-box.

Check one:

- ☐ Chapter 7
☐ Chapter 9

☒ Chapter 11. *Check all that apply:*

- ☐ The debtor is a small business debtor as defined in 11 U.S.C. § 101(51D), and its aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$3,024,725. If this sub-box is selected, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return or if any of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).
- ☒ The debtor is a debtor as defined in 11 U.S.C. § 1182(1), its aggregate noncontingent liquidated debts (excluding debts owed to insiders or affiliates) are less than \$7,500,000, **and it chooses to proceed under Subchapter V of Chapter 11.** If this sub-box is selected, attach the most recent balance sheet, statement of operations, cash-flow statement, and federal income tax return, or if any of these documents do not exist, follow the procedure in 11 U.S.C. § 1116(1)(B).
- ☒ A plan is being filed with this petition.
- ☐ Acceptances of the plan were solicited prepetition from one or more classes of creditors, in accordance with 11 U.S.C. § 1126(b).
- ☐ The debtor is required to file periodic reports (for example, 10K and 10Q) with the Securities and Exchange Commission according to § 13 or 15(d) of the Securities Exchange Act of 1934. File the *Attachment to Voluntary Petition for Non-Individuals Filing for Bankruptcy under Chapter 11* (Official Form 201A) with this form.
- ☐ The debtor is a shell company as defined in the Securities Exchange Act of 1934 Rule 12b-2.

☐ Chapter 12

Debtor SevenScore Pharmaceuticals, LLC Case number (if known) _____
 Name

9. Were prior bankruptcy cases filed by or against the debtor within the last 8 years?

☒ No

☐ Yes. District _____ When _____ Case number _____
 MM / DD / YYYY

If more than 2 cases, attach a separate list.

District _____ When _____ Case number _____
 MM / DD / YYYY

10. Are any bankruptcy cases pending or being filed by a business partner or an affiliate of the debtor?

☐ No

☒ Yes. Debtor See Annex 1 Relationship _____

District _____ When _____
 MM / DD / YYYY

List all cases. If more than 1, attach a separate list.

Case number, if known _____

11. Why is the case filed in this district?

Check all that apply:

☒ Debtor has had its domicile, principal place of business, or principal assets in this district for 180 days immediately preceding the date of this petition or for a longer part of such 180 days than in any other district.

☒ A bankruptcy case concerning debtor's affiliate, general partner, or partnership is pending in this district.

12. Does the debtor own or have possession of any real property or personal property that needs immediate attention?

☒ No

☐ Yes. Answer below for each property that needs immediate attention. Attach additional sheets if needed.

Why does the property need immediate attention? (Check all that apply.)

☐ It poses or is alleged to pose a threat of imminent and identifiable hazard to public health or safety.

What is the hazard? _____

☐ It needs to be physically secured or protected from the weather.

☐ It includes perishable goods or assets that could quickly deteriorate or lose value without attention (for example, livestock, seasonal goods, meat, dairy, produce, or securities-related assets or other options).

☐ Other _____

Where is the property?

Number _____ Street _____

City _____ State ZIP Code _____

Is the property insured?

☐ No

☐ Yes. Insurance agency _____

Contact name _____

Phone _____

Statistical and administrative information

Debtor SevenScore Pharmaceuticals, LLC
Name

Case number (if known) _____

13. Debtor's estimation of available funds

Check one:

- ☒ Funds will be available for distribution to unsecured creditors.
- ☐ After any administrative expenses are paid, no funds will be available for distribution to unsecured creditors.

14. Estimated number of creditors

- | | | |
|--|--|--|
| <input checked="" type="checkbox"/> 1-49 | <input type="checkbox"/> 1,000-5,000 | <input type="checkbox"/> 25,001-50,000 |
| <input type="checkbox"/> 50-99 | <input type="checkbox"/> 5,001-10,000 | <input type="checkbox"/> 50,001-100,000 |
| <input type="checkbox"/> 100-199 | <input type="checkbox"/> 10,001-25,000 | <input type="checkbox"/> More than 100,000 |
| <input type="checkbox"/> 200-999 | | |

15. Estimated assets

- | | | |
|---|--|--|
| <input type="checkbox"/> \$0-\$50,000 | <input type="checkbox"/> \$1,000,001-\$10 million | <input type="checkbox"/> \$500,000,001-\$1 billion |
| <input type="checkbox"/> \$50,001-\$100,000 | <input type="checkbox"/> \$10,000,001-\$50 million | <input type="checkbox"/> \$1,000,000,001-\$10 billion |
| <input checked="" type="checkbox"/> \$100,001-\$500,000 | <input type="checkbox"/> \$50,000,001-\$100 million | <input type="checkbox"/> \$10,000,000,001-\$50 billion |
| <input type="checkbox"/> \$500,001-\$1 million | <input type="checkbox"/> \$100,000,001-\$500 million | <input type="checkbox"/> More than \$50 billion |

16. Estimated liabilities

- | | | |
|--|--|--|
| <input type="checkbox"/> \$0-\$50,000 | <input checked="" type="checkbox"/> \$1,000,001-\$10 million | <input type="checkbox"/> \$500,000,001-\$1 billion |
| <input type="checkbox"/> \$50,001-\$100,000 | <input type="checkbox"/> \$10,000,001-\$50 million | <input type="checkbox"/> \$1,000,000,001-\$10 billion |
| <input type="checkbox"/> \$100,001-\$500,000 | <input type="checkbox"/> \$50,000,001-\$100 million | <input type="checkbox"/> \$10,000,000,001-\$50 billion |
| <input type="checkbox"/> \$500,001-\$1 million | <input type="checkbox"/> \$100,000,001-\$500 million | <input type="checkbox"/> More than \$50 billion |

Request for Relief, Declaration, and Signatures

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

17. Declaration and signature of authorized representative of debtor

The debtor requests relief in accordance with the chapter of title 11, United States Code, specified in this petition.

I have been authorized to file this petition on behalf of the debtor.

I have examined the information in this petition and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 05/09/2023
MM / DD / YYYY

X

Signature of authorized representative of debtor

Title Chief Restructuring Officer

Lawrence R. Perkins

Printed name

Debtor SevenScore Pharmaceuticals, LLC
Name

Case number (if known) _____

18. Signature of attorney

X /s/ R. Craig Martin

Signature of attorney for debtor

Date 05/09/2023

MM / DD / YYYY

R. Craig Martin

Printed name

DLA Piper LLP (US)

Firm name

1201 North Market Street Suite 2100

Number Street

Wilmington

City

(302) 468 -5700

Contact phone

DE 19801

State ZIP Code

craig.martin@us.dlapiper.com

Email address

5032

Bar number

DE

State

ANNEX 1

Pending Bankruptcy Cases

On the date hereof, each of the entities below (collectively the “Debtors”) filed a voluntary petition for relief under chapter 11 of title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware and elected to proceed under subchapter V thereunder. The Debtors have moved for joint administration of these cases under the case number assigned to the subchapter V case of Vyera Pharmaceuticals, LLC:

- Vyera Pharmaceuticals, LLC
- SevenScore Pharmaceuticals, LLC
- Oakrum Pharma, LLC
- Dermelix Biotherapeutics, LLC
- Phoenixus AG
- Orpha Labs AG

**UNANIMOUS WRITTEN CONSENT
OF THE BOARD OF DIRECTORS OF
SEVENSCORE PHARMACEUTICALS, LLC**

Dated: May 9, 2023

The undersigned, being the sole member of the board of directors (the “Board”) of SevenScore Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), in accordance with the authority contained in Section 18-302(d) of the Delaware Limited Liability Company Act (the “Act”), does hereby consent in writing that the following resolutions shall have the same force and effect as if duly adopted at a meeting of the Board, duly noticed, called and held in accordance with the Act.

A. Bankruptcy Filing

WHEREAS, the Board has had the opportunity to consult with the Company’s management team and the Company’s legal and financial advisors and has considered fully various strategic alternatives available to the Company under the circumstances; and

WHEREAS, the Board has determined after consulting with the Company’s management team and the Company’s legal and financial advisors that it is in the best interests of the Company to avail the Company of the protections afforded by chapter 11 of the United States Bankruptcy Code, 11 U.S.C. § 101 *et seq.* (the “Bankruptcy Code”), including subchapter V thereunder, by filing a voluntary petition to commence a case under chapter 11 of the Bankruptcy Code.

NOW, THEREFORE, BE IT:

RESOLVED, that any authorized officer of the Company (an “Authorized Person”), acting solely or jointly, be, and each hereby is, authorized, empowered, and directed, with full power of delegation, to negotiate, execute, deliver, file with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), and perform, in the name and on behalf of the Company, all plans, petitions, schedules, statements, motions, lists, purchase and sale agreements, assumption or assignment agreements, other transactional agreements and documents, applications, pleadings, papers, affidavits, declarations, orders, and other documents in connection with the filing of a voluntary petition seeking relief under the Bankruptcy Code (collectively, the “Bankruptcy Filings”), with such changes therein and additions thereto as any such Authorized Person may deem necessary, appropriate, or advisable, the execution and delivery of any of the Bankruptcy Filings by any such Authorized Person with any changes thereto to be conclusive evidence that any such Authorized Person deemed such changes to meet such standard; and it is further

RESOLVED, that with respect to the Company, each Authorized Person, in each case, acting solely or jointly, be, and each hereby is, authorized, empowered, and directed, with full power of delegation, in the name and on behalf of the Company, to take and perform any and all further acts and deeds that such Authorized Person, in consultation with the Company’s legal and

financial advisors, deems necessary, appropriate, or desirable in connection with the Company's bankruptcy case (the "Bankruptcy Case") or the Bankruptcy Filings including, without limitation, (i) the payment of wages, salaries, fees, expenses, and taxes such Authorized Person deems necessary, appropriate, or desirable, and (ii) negotiating, executing, delivering, performing, and filing any and all additional plans, pleadings, documents, schedules, statements, lists, papers, agreements, certificate, or instruments (or any amendments or modifications thereto) in connection with, or in furtherance of, such Bankruptcy Case with a view to the successful prosecution of such Bankruptcy Case, with such acts to be conclusive evidence such Authorized Person deemed the same to meet such standard; and it is further

B. Retention of Advisors

RESOLVED, that with respect to the Company, each Authorized Person be, and each hereby is, authorized and directed to employ the law firm of DLA Piper LLP (US) ("DLA") as general bankruptcy counsel to represent and assist the Company in carrying out its duties under the Bankruptcy Code, and to take any and all actions to advance the Company's rights and obligations, including, but not limited to, the filing of any pleadings, and in connection therewith, each of the Authorized Persons, with power of delegation, is hereby authorized and directed to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed an appropriate application for authority to retain the services of DLA; and it is further

RESOLVED, that with respect to the Company, each Authorized Person be, and each hereby is, authorized and directed to employ the firm of Sierra Constellation Partners LLC to perform the services of Chief Restructuring Officer (indirectly through the appointment of Lawrence Perkins in such capacity) and as financial advisor (the "Financial Advisor"), to represent and assist the Company in carrying out its duties under the Bankruptcy Code, and to take any and all actions to advance the Company's rights and obligations, and in connection therewith, each of the Authorized Persons with power of delegation, is hereby authorized and directed to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed an appropriate application for authority to retain the services of the Financial Advisor; and it is further

RESOLVED, that with respect to the Company, each Authorized Person be, and each hereby is, authorized and directed to employ the firm of Alvarez & Marsal Securities, LLC as investment banker (the "Investment Banker"), to represent and assist the Company in carrying out its duties under the Bankruptcy Code, and to take any and all actions to advance the Company's rights and obligations and in connection therewith, each of the Authorized Persons with power of delegation, is hereby authorized and directed to execute appropriate retention agreements, pay appropriate retainers, and to cause to be filed an appropriate application for authority to retain the services of the Investment Banker; and it is further

RESOLVED, that with respect to the Company, each Authorized Person be, and each hereby is, authorized and directed to employ Epiq Corporate Restructuring, LLC as notice, claims, and balloting agent and as administrative advisor (the "Claims Agent"), to represent and assist the Company in carrying out its duties under the Bankruptcy Code, and to take any and all actions to advance the Company's rights and obligations and in connection therewith, each of the Authorized Persons with power of delegation, is hereby authorized and directed to execute appropriate

retention agreements, pay appropriate retainers, and to cause to be filed an appropriate application for authority to retain the services of the Investment Banker; and it is further

C. Sale Process

RESOLVED, that the Company, as debtor and debtor in possession in the Bankruptcy Case, shall be, and hereby is, authorized to pursue and implement a sale transaction under section 363 of the Bankruptcy Code or otherwise of all or substantially all of the Company's assets or equity interests, will be presented to the Board following the date hereof and as may be further approved, modified, or amended by one or more of the Authorized Persons in its reasonable judgment and in consultation with the Company's professionals (each, a "Sale"); and it is further

RESOLVED, that the Company, as debtor and debtor in possession in the Bankruptcy Case, shall be, and hereby is, authorized to execute, deliver, and perform its obligations under one or more purchase agreements, license agreements, or other transactions agreements and all associated agreements, schedules, certificates, instruments, guaranties, notices, and other documents implementing a Sale, as may be deemed necessary or desirable by any of the Authorized Persons; and it is further

D. Chapter 11 Plan

RESOLVED, that the Company, as debtor and debtor in possession in the Bankruptcy Case, shall be, and hereby is, authorized to (i) execute and file a plan of reorganization or liquidation, associated disclosure statement, to the extent applicable, and all other related documents, and consummate, and perform under, the transactions contemplated therein and/or (ii) dismiss or close the Bankruptcy Case and execute all related documents as may be reasonably necessary or desirable in the best interests of the Company and its stakeholders; and it is further

E. General Authorization


RESOLVED, that with respect to the Company, each of the Authorized Persons may act, solely or jointly, be, and each hereby is, authorized, empowered, and directed, with full power of delegation, in the name and on behalf of the Company, to take, cause to be taken, or perform any and all further acts or deeds, including, without limitation, (i) the negotiation of such additional agreements, amendments, modifications, supplements, reports, documents, instruments, applications, notes or certificates not now known but which may be required, (ii) the execution, delivery and filing (if applicable) of any of the foregoing, and (iii) the payment of all fees, consent payments, taxes, and other expenses as any such Authorized Person, in his or her sole discretion, may approve or deem necessary, appropriate, or desirable to carry out the intent and accomplish the purposes of the foregoing resolutions and the transactions contemplated thereby, all of such actions, executions, deliveries, filings, and payments to be conclusive evidence of such approval or that such Authorized Person deemed the same to meet such standard.

A signed copy of this Consent delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned has executed this Consent as of the date first written above.

SEVENSCORE PHARMACEUTICALS, LLC

DocuSigned by:

By: A271D5AE6C14495
Name: Thomas J. Allison
Its: Sole Manager

[Signature Page to Resolutions]

Fill in this information to Identify the case:

Debtor Name: SevenScore Pharmaceuticals, LLC

United States Bankruptcy Court for the: District of Delaware

Case Number (If known):

☐ Check if this is an amended filing

Official Form 204

Chapter 11 or Chapter 9 Cases: Consolidated List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders

12/15

A consolidated list of creditors holding the 20 largest unsecured claims must be filed in a Chapter 11 or Chapter 9 case. Include claims which the debtor disputes. Do not include claims by any person or entity who is an insider, as defined in 11 U.S.C. § 101(31). Also, do not include claims by secured creditors, unless the unsecured claim resulting from inadequate collateral value places the creditor among the holders of the 20 largest unsecured claims.

	Name of creditor and complete mailing address, including zip code	Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
					Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
1	DUANE MORRIS LLP 30 S. 17TH STREET PHILADELPHIA, PA 19103	CONTACT: CYNTHIA BALDWIN, VICE PRESIDENT, GENERAL COUNSEL PHONE: 215-979-1000 FAX: 215-979-1020 ALABBONIZIO@DUANEMORRIS.COM	LITIGATION	C, D			\$2,127,923.43
2	CARDINAL HEALTH, INC. 7000 CARDINAL PLACE DUBLIN, OH 43017	CONTACT: GENERAL COUNSEL PHONE: 614-757-5000 KEVIN.MORAN@CARDINALHEALTH.COM; ERICH.TIMMERMAN@CARDINALHEALTH.COM	TRADE PAYABLE				\$452,547.17
3	ANI PHARMACEUTICALS INC. 210 MAIN ST WEST BAUDETTE, MN 56623	CONTACT: NIKHIL LALWANI, CEO PHONE: 218-634-3500 FAX: 218-634-3540 INFO@ANIPHARMACEUTICALS.COM	ROYALTY PAYABLE				\$439,696.00
4	AUCTA PHARMACEUTICALS, INC. 71 SUTTONS LANE PISCATAWAY, NJ 08854	CONTACT: SHOUFENG LI, CEO PHONE: 909-342-4793 FAX: 732-605-6902 SHOUFENG.LI@AUCTAPHARMA.COM	ROYALTY PAYABLE				\$288,705.21

Debtor: SevenScore Pharmaceuticals, LLC

Case Number (if known):

Name of creditor and complete mailing address, including zip code	Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
				Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
5 CONNECTICUT DEPARTMENT OF PUBLIC HEALTH ATTN: CONNECTICUT DRUG ASSISTANCE PROGRAM 410 CAPITOL AVENUE MS#13ACT HARTFORD, CT 06134	CONTACT: GENERAL COUNSEL PHONE: 860-509-8000 FAX: 860-509-7160 ASK.DPH@CT.GOV	TRADE PAYABLE				\$265,853.99
6 ASD SPECIALTY HEALTHCARE INC. 5025 PLANO PARKWAY CARROLLTON, TX 75010	CONTACT: GENERAL COUNSEL PHONE: 800-547-9413 SERVICE@ASDHEALTHCARE.COM	TRADE PAYABLE				\$203,977.57
7 EVERSANA LIFE SCIENCE SERVICES, LLC 190 N. MILWAUKEE STREET MILWAUKEE, WI 53202	CONTACT: JIM LANG, CEO PHONE: 414-299-4900 INDIA@EVERSANA.COM	TRADE PAYABLE	U, D			\$148,458.14
8 COMMONWEALTH OF MASSACHUSETTS MASSHEALTH DRUG REBATE PROGRAM P.O. BOX 3070 BOSTON, MA 02241-3070	CONTACT: GENERAL COUNSEL PHONE: 800-841-2300 MASSHEALTHDRUGLIST@STATE.MA.US	TRADE PAYABLE				\$107,212.61
9 DEPARTMENT OF HEALTH CARE SERVICES DEPT OF HEALTH CARE SERVICES, ACCOUNTING MEDICAL DRUG REBATE AR, MS 1101 P.O. BOX 997415 SACRAMENTO, CA 95899-7413	CONTACT: GENERAL COUNSEL PHONE: 888-452-8609 MMCDOMBUDSMANOFFICE@DHCS.CA.GOV	TRADE PAYABLE				\$101,330.21
10 INTEGRICHAIN, INC. 8 PENN CENTER, 3RD FLOOR 1628 JFK BLVD PHILADELPHIA, PA 19103	CONTACT: LEIGH ANNE SIINO, EXECUTIVE DIRECTOR, SALES PHONE: 609-806-5005 ISIINO@INTEGRICHAIN.COM	TRADE PAYABLE				\$73,838.16
11 WALGREENS SPECIALTY 500 NOBLESTOWN ROAD ATTN: KRISTEN BERGER CARNEGIE, PA 15106	CONTACT: GENERAL COUNSEL PHONE: 888-347-3416 FAX: 412-325-6505 MEDIA@WALGREENS.COM	TRADE PAYABLE				\$72,178.41
12 MCKESSON 401 MASON ROAD LAVERGNE, TN 37086	CONTACT: BRIAN TYLER, CEO PHONE: 972-446-4800 MEDIARELATIONS@MCKESSON.COM	TRADE PAYABLE				\$70,180.62
13 DEPARTMENT OF MEDICAL ASSISTANCE, COMMONWEALTH OF VIRGINIA CMS MEDICAID DRUG REBATE UNIT ATTN: FISCAL UNIT 600 E. BROAD ST., SUITE 1300 RICHMOND, VA 23219-1857	CONTACT: GENERAL COUNSEL PHONE: 888-221-1590 VAMEDICAIDMEDIAREQUEST@DMAS.VIRGINIA.GOV	TRADE PAYABLE				\$69,000.00

Debtor: SevenScore Pharmaceuticals, LLC

Case Number (if known):

	Name of creditor and complete mailing address, including zip code	Name, telephone number, and email address of creditor contact	Nature of the claim (for example, trade debts, bank loans, professional services, and government contracts)	Indicate if claim is contingent, unliquidated, or disputed	Amount of unsecured claim If the claim is fully unsecured, fill in only unsecured claim amount. If claim is partially secured, fill in total claim amount and deduction for value of collateral or setoff to calculate unsecured claim.		
					Total claim, if partially secured	Deduction for value of collateral or setoff	Unsecured claim
14	TREASURER STATE OF FL AGENCY FOR HEALTHCARE ADMINISTRATION FINANCE & ACCOUNTING 2727 MAHAN DRIVE, MAIL STOP #14 TALLAHASSEE, FL 32308	CONTACT: GENERAL COUNSEL PHONE: 850-413-2761 WEBMASTER@AHCA.MYFLO RIDA.COM	TRADE PAYABLE				\$65,547.88
15	OPTUMRX, INC 5701 KATELLA AVENUE, CA120-0308 CYPRESS, CA 90630	CONTACT: MELANIE FREEMAN, COMPLIANCE AND PRIVACY OFFICER PHONE: 714-825-3600 MELANIE.FREEMAN@OPTUM .COM	TRADE PAYABLE				\$63,000.00
16	CBIZ ACCOUNTING, TAX & ADVISORY OF NEW YORK, LLC 1065 AVENUE OF THE AMERICAS 10TH FLOOR NEW YORK, NY 10018	CONTACT: ERIK LINN, MANAGING PARTNER PHONE: 212-790-5790 FAX: 703-563-9318 INFO@CROSSCOUNTRY- CONSULTING.COM	TRADE PAYABLE				\$52,500.00
17	PROPHARMA GROUP 2635 UNIVERSITY AVENUE WEST SUITE 195 ST. PAUL, MN 55114	CONTACT: MICHAEL STOMBERG, CEO PHONE: 916-663-2729 INFO@PROPHARMAGROUP. COM	TRADE PAYABLE				\$51,905.00
18	AGENCY FOR HEALTH CARE ADMINISTRATION FINANCE AND ACCOUNTING/DRUG REBATE 2727 MAHAN DR. MAIL STOP #14 TALLAHASSEE, FL 32308	CONTACT: GENERAL COUNSEL PHONE: 888-419-3456 WEBMASTER@AHCA.MYFLO RIDA.COM	TRADE PAYABLE				\$48,978.63
19	TREASURER STATE OF OHIO MEDICAID DRUG REBATE 30 E. BROAD STREET - 9TH FLOOR COLUMBUS, OH 43215	CONTACT: GENERAL COUNSEL PHONE: 800-324-8680 CONSTITUENTAFFAIRS@TOS. OHIO.GOV; ECONOMICDEVELOPMENT@ TOS.OHIO.GOV	TRADE PAYABLE				\$48,752.27
20	DEPARTMENT OF HUMAN SERVICES/DRUG REBATE PROGRAM P.O. BOX 780634 PHILADELPHIA, PA 19178-0634	CONTACT: GENERAL COUNSEL PHONE: 717-787-2500 RA- PWDHSPRESSOFFICE@PA.GO V; BCWALINA@PA.GOV; ALFOGARTY@PA.GOV	TRADE PAYABLE				\$36,823.57

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

SevenScore Pharmaceuticals, LLC,

Debtor.

Chapter 11, Subchapter V

Case No. 23-____ (____)

CORPORATE OWNERSHIP STATEMENT

Pursuant to Rules 1007(a)(1) and 7007.1 of the Federal Rules of Bankruptcy Procedure and Rule 1007-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware, SevenScore Pharmaceuticals, LLC hereby certifies that the following corporate entity owns the below-specified percentage of SevenScore Pharmaceuticals, LLC's equity interests, as of the date hereof.

Entity	Percentage Interest
Phoenixus AG	100%

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

SevenScore Pharmaceuticals, LLC,

Debtor.

Chapter 11, Subchapter V

Case No. 23-____ (___)

LIST OF EQUITY SECURITY HOLDERS

Pursuant to Rule 1007(a)(3) of the Federal Rules of Bankruptcy Procedure and Rule 1007-1 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware, SevenScore Pharmaceuticals, LLC hereby provides the following list of holders of equity interests:

Name and Address of Interest Holder	Percentage Interest
Phoenixus AG Haldenstrasse 5, 6340 Baar, Switzerland	100%

Fill in this information to identify the case and this filing:

Debtor Name SevenScore Pharmaceuticals, LLC

United States Bankruptcy Court for the: _____ District of DE
(State)

Case number (If known): _____

Official Form 202**Declaration Under Penalty of Perjury for Non-Individual Debtors****12/15**

An individual who is authorized to act on behalf of a non-individual debtor, such as a corporation or partnership, must sign and submit this form for the schedules of assets and liabilities, any other document that requires a declaration that is not included in the document, and any amendments of those documents. This form must state the individual's position or relationship to the debtor, the identity of the document, and the date. Bankruptcy Rules 1008 and 9011.

WARNING -- Bankruptcy fraud is a serious crime. Making a false statement, concealing property, or obtaining money or property by fraud in connection with a bankruptcy case can result in fines up to \$500,000 or imprisonment for up to 20 years, or both. 18 U.S.C. §§ 152, 1341, 1519, and 3571.

Declaration and signature


I am the president, another officer, or an authorized agent of the corporation; a member or an authorized agent of the partnership; or another individual serving as a representative of the debtor in this case.

I have examined the information in the documents checked below and I have a reasonable belief that the information is true and correct:

- ☐ *Schedule A/B: Assets—Real and Personal Property* (Official Form 206A/B)
- ☐ *Schedule D: Creditors Who Have Claims Secured by Property* (Official Form 206D)
- ☐ *Schedule E/F: Creditors Who Have Unsecured Claims* (Official Form 206E/F)
- ☐ *Schedule G: Executory Contracts and Unexpired Leases* (Official Form 206G)
- ☐ *Schedule H: Codebtors* (Official Form 206H)
- ☐ *Summary of Assets and Liabilities for Non-Individuals* (Official Form 206Sum)
- ☐ Amended Schedule _____
- ☒ *Chapter 11 or Chapter 9 Cases: List of Creditors Who Have the 20 Largest Unsecured Claims and Are Not Insiders* (Official Form 204)
- ☒ Other document that requires a declaration Corporate Ownership Statement; List of Equity Security Holders

I declare under penalty of perjury that the foregoing is true and correct.

Executed on 05/09/2023
MM / DD / YYYY

 /s/ Lawrence R. Perkins
Signature of individual signing on behalf of debtor

Lawrence R. Perkins
Printed name

Chief Restructuring Officer
Position or relationship to debtor

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

SevenScore Pharmaceuticals, LLC,

Debtor.

Chapter 11, Subchapter V

Case No. 23-____ (____)

STATEMENT PURSUANT TO 11 U.S.C. § 1116

I, Lawrence R. Perkins, hereby declare under penalty of perjury:

1. Debtor SevenScore Pharmaceuticals, LLC has not prepared a statement of operations or cash-flow statement.
2. Debtor SevenScore Pharmaceuticals, LLC has prepared a balance sheet and income statement, which have been appended to its voluntary petition for relief.
3. Debtor SevenScore Pharmaceuticals, LLC has not filed a federal tax return.

Dated: May 9, 2023

/s/ Lawrence R. Perkins

By: Lawrence R. Perkins

Its: Chief Restructuring Officer

	Phoenixus AG	Vyera LLC	Oakrum LLC	Regnum ¹	Sevenscore	Orpha Labs AG	Dermelix	Elimination Regnum	Eliminations	Consolidated Apr 30, 2023
Assets										
Cash and Cash Equivalents	1,619,837	7,950,405	3,890,296	390,788	338,851	178,677	-	-	-	14,368,854
Restricted Cash - PNC CD	-	-	-	-	-	-	-	-	-	-
Accounts Receivable	-	(242,763)	993,608	-	-	-	-	-	-	750,845
Intercompany	21,880,506	10,398,210	(13,704,453)	(1,775,600)	(4,321,714)	(8,399,346)	(3,677,078)	(391,000)	(9,525)	-
Inventory	58,248	4,128,544	73,539	-	-	-	-	-	(4,054,260)	206,071
Prepaid and Other Assets	1,982,850	418,059	32,191	17,351	-	1,020	-	-	-	2,451,471
Total Current Assets	25,541,441	22,652,455	(8,714,820)	(1,367,461)	(3,982,863)	(8,219,648)	(3,677,078)	(391,000)	(4,063,786)	17,777,240
Property and Equipment, net	-	0	-	-	-	-	-	-	-	0
Daraprim Product Rights	55,919,306	-	-	-	-	-	-	-	-	55,919,306
Daraprim Product Rights Accum Amort	(55,919,305)	-	-	-	-	-	-	-	-	(55,919,305)
In Process Research & Development	-	-	-	-	-	-	-	-	-	-
Other Product Rights	98,691	-	-	-	-	-	-	-	-	98,691
Goodwill	3,130,616	-	-	-	-	-	-	-	-	3,130,616
Other Long Term Assets	-	131,516	800,000	-	-	-	-	-	-	931,516
Total Assets	28,770,749	22,783,971	(7,914,820)	(1,367,461)	(3,982,863)	(8,219,648)	(3,677,078)	(391,000)	(4,063,786)	21,938,064
Liabilities and Stockholder's Equity (Deficiency)										
Accounts Payable	71,562	(15,272)	458,133	0	(0)	2,500	-	-	-	516,923
Accrued Expenses	858,575	1,986,290	2,450,831	15,424	-	-	-	-	-	5,311,121
CMS Liabilities	-	3,375,922	266,141	-	-	-	-	-	-	3,642,063
Wage and Bonus Payables	101,796	455,421	11,374	51,968	-	-	-	-	-	620,559
Taxes Payable	-	(89,999)	(50)	800	(50)	-	-	-	-	(89,299)
Current Liabilities	1,031,934	5,712,362	3,186,429	68,192	(50)	2,500	-	-	-	10,001,367
Capital Lease	-	131,517	-	-	-	-	-	-	-	131,517
Long Term Loan	-	-	-	-	-	-	-	-	-	-
Warrant Derivative Liability	-	-	-	-	-	-	-	-	-	-
Total Liabilities	1,031,934	5,843,879	3,186,429	68,192	(50)	2,500	-	-	-	10,132,884
Par Value & APIC	83,111,415	2,983,371	-	41,500	100	-	-	(41,500)	1,208	86,096,094
Accumulated Deficit	(57,034,289)	13,956,721	(11,101,249)	(1,477,153)	(3,982,913)	(8,222,148)	(3,677,078)	(349,500)	(7,440,471)	(79,328,080)
AOCI	4,644,515	-	-	-	-	-	-	-	392,651	5,037,166
Total Equity	30,721,641	16,940,092	(11,101,249)	(1,435,653)	(3,982,813)	(8,222,148)	(3,677,078)	(391,000)	(7,046,612)	11,805,180
Total Liabilities and Equity	31,753,575	22,783,971	(7,914,820)	(1,367,461)	(3,982,863)	(8,219,648)	(3,677,078)	(391,000)	(7,046,612)	21,938,064

¹ Regnum is a non-debtor

Phoenixus Consolidated	Jan-23	Feb-23	Mar-23	Apr-23	YTD 2023
Gross Sales	\$ 1,881,308	\$ 2,073,794	\$ 2,092,039	\$ 1,734,196	\$ 7,781,337
Sales Discounts	\$ 1,167,317	\$ 1,281,892	\$ 1,481,415	\$ 1,227,469	\$ 5,158,093
CMS Allowance	\$ 359,289	\$ 440,774	\$ (149,383)	\$ 243,865	\$ 894,545
Sales Allowances					\$ -
DLSS Fees	\$ 15,025	\$ 11,100	\$ 798	\$ 4,701	\$ 31,624
Net Sales	\$ 339,677	\$ 340,028	\$ 759,209	\$ 258,161	\$ 1,697,075
Interco Sales	\$ 146,499	\$ (40,602)	\$ (110,773)	\$ 51,674	\$ 46,799
Interco COGS	\$ (133,916)	\$ (50,047)	\$ (669,687)	\$ (136,530)	\$ (990,180)
Profit Share	\$ (13,878)	\$ (17,093)	\$ (2,495)	\$ 2,454	\$ (31,012)
Cost of Goods Sold	\$ (13,101)	\$ 55,350	\$ 918,024	\$ 92,886	\$ 1,053,160
Total Cost of Goods Sold	\$ (14,396)	\$ (52,391)	\$ 135,070	\$ 10,485	\$ 78,767
Gross Profit	\$ 354,073	\$ 392,419	\$ 624,139	\$ 247,676	\$ 1,618,308
Salaries & Wages	\$ 623,548	\$ 776,787	\$ 517,823	\$ 588,477	\$ 2,506,635
Outsourcing Expenses	\$ 155,321	\$ 222,921	\$ 255,237	\$ 188,899	\$ 822,379
Travel	\$ 57,688	\$ 15,436	\$ (13,266)	\$ 1,590	\$ 61,448
Milestone Payments	\$ -	\$ -	\$ -	\$ -	\$ -
Royalties	\$ 4,797	\$ 5,249	\$ 1,291	\$ (36)	\$ 11,301
Data Subscriptions	\$ 31,270	\$ 21,054	\$ 38,619	\$ 17,823	\$ 108,767
IT Outsourcing	\$ 16,935	\$ 14,236	\$ 16,895	\$ 18,754	\$ 66,820
Legal Expenses	\$ 485,308	\$ 456,802	\$ 803,780	\$ 734,465	\$ 2,480,355
Rent	\$ 21,402	\$ 21,991	\$ 20,581	\$ 20,947	\$ 84,920
Amortization	\$ 1,173	\$ 1,173	\$ 1,172	\$ 1,207	\$ 4,725
Insurance	\$ 346,335	\$ 345,486	\$ 319,662	\$ 480,691	\$ 1,492,174
Advertising and Promo Materials	\$ -	\$ -	\$ 249	\$ -	\$ 249
Distribution Costs	\$ 6,223	\$ 6,500	\$ 22,394	\$ 22,406	\$ 57,523
Recruitment & Agency Fees			\$ -	\$ -	\$ -
Donations & Grants					\$ -
Conferences & Seminars	\$ -	\$ 386	\$ -	\$ 675	\$ 1,061
Business Permits & Licenses			\$ 1,820	\$ -	\$ 1,820
Regulatory Fees			\$ -	\$ -	\$ -
Registrations and Filing Fees	\$ 2,221	\$ 1,170	\$ 4,562	\$ 9,922	\$ 17,876
Accounting Services	\$ 115,199	\$ 144,073	\$ 157,245	\$ 91,875	\$ 508,392
Office Supplies & Exp	\$ 7,735	\$ 23	\$ 2,665	\$ 2,604	\$ 13,028
Postage & deliver	\$ 1,438	\$ 793	\$ 224	\$ 333	\$ 2,788
Telephone Office/Wireless	\$ 3,307	\$ 5,006	\$ 3,988	\$ 4,959	\$ 17,261
Bank Service Charges	\$ 1,296	\$ 568	\$ (403)	\$ 810	\$ 2,271
ADP Fees	\$ 2,133	\$ 2,594	\$ 3,265	\$ 998	\$ 8,991
Depreciation	\$ -	\$ -	\$ -	\$ -	\$ -
GAO	\$ 0	\$ (0)	\$ 0		\$ 0
Taxes	\$ -	\$ -	\$ -	\$ -	\$ -
Total Operating Expense	\$ 1,883,330	\$ 2,042,250	\$ 2,157,804	\$ 2,187,398	\$ 8,270,782
Operating Income / (Loss)	\$ (1,529,257)	\$ (1,649,830)	\$ (1,533,665)	\$ (1,939,722)	\$ (6,652,473)
Other Income / (Expense):					\$ -
Interest Expense		\$ -	\$ -	\$ (605)	\$ (605)
Interest Income	\$ 130	\$ 130	\$ 118	\$ 130	\$ 508
Intercompany Transfer Price	\$ (1)	\$ 5	\$ 29	\$ (7)	\$ 26
Intercompany Interest Exp_Inc			\$ (0)		\$ (0)
Foreign Exchange Gains / Losses	\$ 180,397	\$ 254,469	\$ (523,294)	\$ (410,911)	\$ (499,339)
Gain/Loss from Legal Proceedings					\$ -
All Other	\$ (61,865)	\$ 868,537	\$ -	\$ -	\$ 806,671
Total Other Operating Expense	\$ 118,660	\$ 1,123,141	\$ (523,148)	\$ (411,393)	\$ 307,261
Net Income / (Loss)	\$ (1,410,596)	\$ (526,689)	\$ (2,056,813)	\$ (2,351,114)	\$ (6,345,213)